IOL Chemicals and Pharmaceuticals begins commercial production of Paracetamol

Paracetamol, also known as Acetaminophen, is an Active Pharma Ingredient (API) that is used to treat fever and mild pain.

Published On 2022-04-25 05:00 GMT   |   Update On 2022-04-25 12:02 GMT
Advertisement

Punjab: IOL Chemicals and Pharmaceuticals Limited has announced that the company has commenced the commercial production of 'Paracetamol' with installed capacity of 1800 MTPA along with backward integration of Para Amino Phenol (PAP) with effect from 22 nd April 2022.

The Company is manufacturing Paracetamol in its existing Unit No 4, which has been converted as multiproduct facility, with a cost of about Rs 100 Lakhs whereas PAP is being manufactured in part of Unit No 9. The Company shall continue to use Unit 4 & Unit 9 for manufacturing other products as per market conditions.

Advertisement

Further, considering the present market scenario, the Company is in the process of enhancing the installed capacity for manufacturing the Paracetamol from 1800 MTPA to 3600 MTPA with a capex of about Rs 25 Crore, which is expected to be completed during the 3 rd quarter of FY 2023. All the capex is being met through internal accruals only.

The Paracetamol, also known as Acetaminophen, is an Active Pharma ingredient (API) that is used to treat fever and mild pain, whereas PAP is used as an intermediate to manufacture Paracetamol.

Read also: IOL Chemicals gets Korean approval for Ibuprofen, Fenofibrate

IOL Chemicals and Pharmaceuticals Limited is an innovation-driven Bulk Drug, Intermediates and Specialty Chemicals Company headquartered in India. Its APIs portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. The company is the backward integrated company producing all Intermediates and Key Starting Materials (KSMs) of ibuprofen.

Read also: USFDA gives its nod to IOL chemicals and pharmaceuticals for a plant in Punjab

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News